Postprandial insulin lispro. A new therapeutic option for type 1 diabetic patients.

@article{Schernthaner1998PostprandialIL,
  title={Postprandial insulin lispro. A new therapeutic option for type 1 diabetic patients.},
  author={Guntram Schernthaner and Wolfgang Wein and K Sandholzer and S Equiluz-Bruck and Peter C. Bates and Martin A. Birkett},
  journal={Diabetes care},
  year={1998},
  volume={21 4},
  pages={570-3}
}
OBJECTIVE For intensified insulin therapy of type 1 diabetes, bolus injection of regular human insulin 30-15 min before a meal is currently recommended. This randomized study is aimed to determine whether insulin lispro (LIS), a new insulin analog with a rapid onset of action, can provide comparable blood glucose (BG) control by injection after the meal. RESEARCH DESIGN AND METHODS Eighteen type 1 diabetic subjects injected regular insulin (REG) at 40, 20, or 0 min before or LIS at 20 or 0… CONTINUE READING
13 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…